Trial Profile
A phase II, multicenter, randomized, double-blind clinical trial to evaluate the efficacy and safety of Tarceva [erlotinib] in combination with Avastin [bevacizumab] versus Avastin alone for treatment of metastatic renal cell carcinoma
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 24 Nov 2014
Price :
$35
*
At a glance
- Drugs Erlotinib (Primary) ; Bevacizumab
- Indications Renal cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors Genentech
- 09 Sep 2009 Planned number of patients (100) added as reported by ClinicalTrials.gov.
- 09 Sep 2009 Planned number of patients (100) added as reported by ClinicalTrials.gov.
- 10 Oct 2007 Results have been published.